KRON TV: AI in Medicine From Research Assistant to Predictive Partner
In a KRON-TV interview, Dotmatics VP Phil Mounteney discusses how AI is evolving from a research assistant automating data tasks to a predictive partner that accelerates drug discovery by identifying new targets, designing molecules, and enabling personalized therapies, ultimately reducing costs and time to market while expanding patient access to safer, tailored medicines.
In this featured interview on KRON-TV San Francisco, Dotmatics VP of Science & Technology, Phil Mounteney, shares how artificial intelligence is transforming drug discovery and development. He explains how AI today serves as a “research assistant,” automating data-heavy tasks and accelerating analysis, but in the near future will act as a true research partner by helping predict new drug targets, design molecules, and enable more personalized therapies.
Phil also highlights why speed matters in healthcare, how AI can significantly reduce the cost and time to bring drugs to market, and how these advances will expand access to safer, more tailored medicines for patients worldwide.
Watch the full interview to discover how Dotmatics is helping researchers harness AI to accelerate breakthroughs and shape the future of medicine.
Related
NBC Las Vegas: AI is Accelerating Drug Discovery and Vaccine Development
In an NBC Las Vegas interview, Phil Mounteney, VP of Science and Technology at Dotmatics, explains how AI is transforming drug discovery and vaccine development by accelerating research timelines, reducing costs, enhancing drug safety through advanced data analysis, and optimizing development pipelines for faster and more efficient medical breakthroughs post-COVID.
NBC Louisiana: How AI is Accelerating Drug Discovery
In an NBC Louisiana feature, Dotmatics’ VP Phil Mounteney explained how AI is revolutionizing drug discovery by significantly reducing development time from up to ten years to potentially half, enhancing efficiency in analyzing vast data sets while ensuring data privacy by keeping sensitive information secure and in-house.
CBS News: How AI Is Accelerating Safer, More Personalized Drug Discovery
In a CBS News interview, Dotmatics VP Phil Mounteney explains how their internally developed AI models accelerate drug discovery by analyzing early-phase research data to shorten development cycles, reduce costs, and deliver safer, personalized therapies while maintaining data privacy.
Gray TV Washington DC: AI helping scientists make drug breakthroughs
The Gray TV Washington DC feature highlights how scientists, including Christian Olsen of Dotmatics, are leveraging AI and machine learning to accelerate drug discovery and expedite bringing new drugs to market.
The Future of AI in Drug Discovery
The Forbes article discusses how AI is revolutionizing drug discovery by accelerating R&D and improving decision-making, highlighting Dotmatics’ role in integrating data and applying AI to scientific workflows, while also connecting these advancements to broader innovations in sustainability and global problem-solving.
Techstrong TV: AI Leadership Insights for Scientific Research and Drug Discovery
In this Techstrong TV interview, Dotmatics CEO Thomas Swalla discusses how the company leverages AI to accelerate scientific research and drug discovery by streamlining workflows, enabling breakthroughs, and reducing costs in R&D.